How Lurbinectedin Works Against Cancer
Lurbinectedin (Zepzelca) is an alkylating agent that binds DNA minor grooves, trapping topoisomerase I and causing double-strand breaks, leading to cancer cell death. Approved by FDA in 2020 for metastatic small cell lung cancer (SCLC) after platinum failure, it primarily kills tumor cells directly rather than boosting immune responses.[1]
Direct Impact on Immune Response
Lurbinectedin has limited direct stimulation of adaptive immunity like T-cell activation seen in checkpoint inhibitors (e.g., PD-1 blockers). Preclinical data show it reduces tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), which dampen antitumor immunity. This indirectly enhances immune cell infiltration into tumors by remodeling the immunosuppressive microenvironment, particularly in SCLC and other solid tumors.[2][3]
Evidence from Studies
In SCLC cell lines and mouse models, lurbinectedin decreased immunosuppressive cytokines (e.g., IL-10, TGF-β) and increased pro-inflammatory markers, correlating with higher CD8+ T-cell activity. A phase II trial (PM14-001) noted objective response rates of 35% in pretreated SCLC patients, with some responses linked to reduced PD-L1 expression on tumors, potentially easing immune evasion.[4] No large-scale trials confirm standalone immune synergy, but its DNA damage may promote immunogenic cell death, releasing neoantigens for immune recognition.[5]
Comparison to Immunotherapies
Unlike Keytruda (pembrolizumab), which blocks PD-1 to unleash T-cells, lurbinectedin lacks direct immunomodulation but complements it. In ovarian cancer models, combining lurbinectedin with anti-PD-1 doubled tumor regression by boosting effector T-cells and reducing exhaustion markers (e.g., TIM-3).[6] Clinical trials (e.g., NCT02454972) explore this pairing in SCLC, where monotherapy immunotherapy response is low (~20%).
When Immune Effects Matter Most
Effects peak in immunosuppressive "cold" tumors like SCLC, where lurbinectedin converts non-inflamed microenvironments to "hot" ones. Patient responses vary by tumor mutation burden; high-TMB cases show stronger indirect immune benefits. Risks include myelosuppression, potentially worsening immune compromise short-term.[7]
Ongoing Trials and Limitations
Phase III trials (e.g., IMforte, NCT04072047) test lurbinectedin with immunotherapy in SCLC, aiming to quantify immune biomarkers like tumor mutational burden or TIL infiltration. Data gaps persist on long-term immune durability versus chemotherapy alone.[8]
Sources
[1]: FDA Approval Summary - Zepzelca (lurbinectedin), fda.gov
[2]: Takebe et al., Clin Cancer Res (2020), PMID 32094148
[3]: Paz-Ares et al., Lancet Oncol (2021), PMID 34051878
[4]: Trigo et al., Lancet Oncol (2020), PMID 32353247
[5]: Vitale et al., Oncoimmunology (2019), PMID 31497638
[6]: Jonsson et al., Cancer Res (2022), PMID 35105625
[7]: Zepzelca Prescribing Information, pharma.us.jnj.com
[8]: ClinicalTrials.gov, NCT04072047